Evidence map›Paper›PMID 39445263›Full record

ReviewCureus2024

Therapeutic Applications of Azo Dye Reduction: Insights From Methyl Orange Degradation for Biomedical Innovations.

Sana Qausain, Mohd Basheeruddin

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sana QausainBiochemistry, Jawaharlal Nehru Medical College, Wardha, IND.
Mohd BasheeruddinBiochemistry, Jawaharlal Nehru Medical College, Wardha, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper emphasizes the possible application of methyl orange reduction as a therapeutic technique, highlighting the potential of azo dye reduction in biomedical fields. The generally used azo dyes are toxic and carcinogenic; hence, they implicitly threaten the environment and health. The degradation of methyl orange, a famous example of azo dyes, is used to describe the degradation process for other azo dyes. This work discusses the ability of different methyl orange degradation methods, focusing on biocatalysts and nanomaterials, among the methods that identified enzymatic degradation with azoreductase enzymes as the method that quickly breaks down azo dyes under mild conditions as the most appropriate method, as well as its specificity as environmentally friendly. Moreover, metal nanoparticles such as silver and gold impellers increase the reducing efficiency because they offer a pivotal surface for the reduction reactions that undergo electron transfer. The complete breakdown of methyl orange is essential in biomedical usage. The strategies for treating azo dye reduction can be extended to next-generation drug delivery systems (DDS), biosensors, and therapeutic agents. Organisms involved in degradation can be functionalized to selectively degrade specific cells or tissues, thus presenting a new targeted therapy. Knowledge of degradation pathways and non-toxic products is essential in creating programs that build better and more efficient therapeutic agents. This work endeavors to illustrate the development of enzymatic and nanomaterials-based approaches to achieve sustainable azo dye decolorisation to open the gateway to developing other biomedical applications that tend to promote environmental and health-friendly solutions.

Indexed as

azo dyebiocatalystsbiomedical applicationsbiosensorsdrug deliveryenzymatic degradationmethyl orangenanomaterialstherapeutic agents

Identifiers

PMID39445263
PMCPMC11496386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.